Severe bleeding complications during antiepileptic treatment with valproic acid in children

E Cannizzaro1, M Albisetti, G Wohlrab

  • 1Division of Haematology and Neurology, University Children's Hospital, Zurich, Switzerland.

Neuropediatrics
|July 4, 2007
PubMed

Insights

Valproic acid (VPA), an antiepileptic drug, can cause severe bleeding in children, including intracranial and postoperative hemorrhage. Early diagnosis and management are crucial to prevent these serious complications in pediatric patients.

Area of Science:

  • Pediatric Neurology
  • Hematology
  • Pharmacology

Background:

  • Valproic acid (VPA) is a widely used antiepileptic medication in pediatric populations.
  • VPA is known to cause laboratory abnormalities related to hemostasis.
  • The clinical significance of VPA-induced hemostatic abnormalities remains debated.

Observation:

  • This study reports on four pediatric cases experiencing severe bleeding complications during VPA therapy.
  • Two children presented with intracranial bleeding.
  • Two children had severe bleeding following surgical procedures.

Findings:

  • The case series highlights the potential for VPA to precipitate serious hemorrhagic events in children.
  • Severe bleeding, including intracranial and postoperative, can occur despite VPA's common use.
  • Diagnostic and therapeutic strategies are essential for managing VPA-associated bleeding risks.

Implications:

  • Clinicians should be vigilant for bleeding complications in children treated with VPA.
  • Prompt diagnostic evaluation and appropriate interventions are necessary to mitigate bleeding risks.
  • This underscores the importance of considering VPA's impact on hemostasis in pediatric care.

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...